Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.
BRCA1 or BRCA2 genes, are implicated in 10-15% of ovarian cancer cases, increased to 22%
germline BRCA1/2 mutation frequency in patients with high grade serous histology subtype,
including those women who have no family history of breast or ovarian cancer. With the rapid
advancement of therapeutics targeted this population, this protocol seeks to provide genetic
BRCA1/2 screening to all patients with high grade serous ovarian cancer. This information
may help in selection of future treatment options and genetic testing for BRCA1/2 may be
used to potentially prevent a proportion of cancer for the family members.
This study will be an opportunity for patient to improve access at genetic and molecular
testing for BRCA1/2 mutation which could impact her future treatment option. Moreover, this
study will allow to prospectively assess the proportion of patients with BRCA mutation in
ovarian cancer and describe the type of mutations identified in a large population.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society